Clinical Trial

Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome

Study acronym: WASFUP
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
An open follow up study of patients enrolled in the Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome and treated with autologous CD34+ cells transduced with the w1.6\_hWASP\_WPRE (VSVg) lentiviral vector.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2015-01-05; most recent amendment 2021-05-31.
Status change: Recruiting → Active, Not Recruiting 2021-05-31
Trial Details
NCT Number NCT02333760
Lead Sponsor Genethon
Conditions Wiskott-Aldrich Syndrome
Enrollment 10 participants
Start Date 2014-09
Primary Completion 2032-10 (estimated)
Study Completion 2032-10 (estimated)
Updated on ClinicalTrials.gov 2021-06-03